Castle Biosciences Q3 2025 slides: test volume surges 36%, revenue beats forecasts
PositiveFinancial Markets

Castle Biosciences has reported a remarkable 36% surge in test volume for Q3 2025, alongside revenues that exceeded forecasts. This impressive growth highlights the company's strong position in the healthcare market, reflecting increased demand for its innovative diagnostic tests. Such performance not only boosts investor confidence but also underscores the importance of advanced testing solutions in improving patient outcomes.
— Curated by the World Pulse Now AI Editorial System











